vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and RANGE RESOURCES CORP (RRC). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $786.9M, roughly 1.5× RANGE RESOURCES CORP). RANGE RESOURCES CORP runs the higher net margin — 22.8% vs -24.1%, a 46.9% gap on every dollar of revenue. On growth, RANGE RESOURCES CORP posted the faster year-over-year revenue change (18.0% vs 12.2%). Over the past eight quarters, RANGE RESOURCES CORP's revenue compounded faster (14.6% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Range Resources Corporation is a natural gas exploration and production company, the headquartered is in Fort Worth, Texas. It operates in the Marcellus Formation, where it is the largest land owners.
ELAN vs RRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $786.9M |
| Net Profit | $-276.0M | $179.1M |
| Gross Margin | 51.5% | 94.5% |
| Operating Margin | -22.6% | — |
| Net Margin | -24.1% | 22.8% |
| Revenue YoY | 12.2% | 18.0% |
| Net Profit YoY | -3350.0% | 88.8% |
| EPS (diluted) | $-0.55 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $786.9M | ||
| Q3 25 | $1.1B | $655.3M | ||
| Q2 25 | $1.2B | $699.6M | ||
| Q1 25 | $1.2B | $846.3M | ||
| Q4 24 | $1.0B | $667.0M | ||
| Q3 24 | $1.0B | $567.9M | ||
| Q2 24 | $1.2B | $513.2M | ||
| Q1 24 | $1.2B | $598.8M |
| Q4 25 | $-276.0M | $179.1M | ||
| Q3 25 | $-34.0M | $144.3M | ||
| Q2 25 | $11.0M | $237.6M | ||
| Q1 25 | $67.0M | $97.1M | ||
| Q4 24 | $-8.0M | $94.8M | ||
| Q3 24 | $364.0M | $50.7M | ||
| Q2 24 | $-50.0M | $28.7M | ||
| Q1 24 | $32.0M | $92.1M |
| Q4 25 | 51.5% | 94.5% | ||
| Q3 25 | 53.4% | 92.5% | ||
| Q2 25 | 57.5% | 95.0% | ||
| Q1 25 | 57.3% | 93.1% | ||
| Q4 24 | 50.9% | 93.7% | ||
| Q3 24 | 52.2% | 94.3% | ||
| Q2 24 | 58.2% | 93.4% | ||
| Q1 24 | 57.3% | 94.7% |
| Q4 25 | -22.6% | — | ||
| Q3 25 | -4.4% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | -5.0% | — | ||
| Q3 24 | 54.3% | — | ||
| Q2 24 | -2.7% | — | ||
| Q1 24 | 1.0% | — |
| Q4 25 | -24.1% | 22.8% | ||
| Q3 25 | -3.0% | 22.0% | ||
| Q2 25 | 0.9% | 34.0% | ||
| Q1 25 | 5.6% | 11.5% | ||
| Q4 24 | -0.8% | 14.2% | ||
| Q3 24 | 35.3% | 8.9% | ||
| Q2 24 | -4.2% | 5.6% | ||
| Q1 24 | 2.7% | 15.4% |
| Q4 25 | $-0.55 | $0.75 | ||
| Q3 25 | $-0.07 | $0.60 | ||
| Q2 25 | $0.02 | $0.99 | ||
| Q1 25 | $0.13 | $0.40 | ||
| Q4 24 | $-0.01 | $0.38 | ||
| Q3 24 | $0.73 | $0.21 | ||
| Q2 24 | $-0.10 | $0.12 | ||
| Q1 24 | $0.06 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $204.0K |
| Total DebtLower is stronger | $3.9B | $1.2B |
| Stockholders' EquityBook value | $6.5B | $4.3B |
| Total Assets | $13.4B | $7.4B |
| Debt / EquityLower = less leverage | 0.60× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $204.0K | ||
| Q3 25 | $505.0M | $175.0K | ||
| Q2 25 | $539.0M | $134.0K | ||
| Q1 25 | $487.0M | $344.6M | ||
| Q4 24 | $468.0M | $304.5M | ||
| Q3 24 | $490.0M | $277.4M | ||
| Q2 24 | $416.0M | $251.1M | ||
| Q1 24 | $345.0M | $343.1M |
| Q4 25 | $3.9B | $1.2B | ||
| Q3 25 | $4.0B | $1.2B | ||
| Q2 25 | $4.1B | $1.2B | ||
| Q1 25 | $4.4B | $1.7B | ||
| Q4 24 | $4.3B | $1.7B | ||
| Q3 24 | $4.4B | $1.7B | ||
| Q2 24 | $5.7B | $1.7B | ||
| Q1 24 | $5.8B | $1.8B |
| Q4 25 | $6.5B | $4.3B | ||
| Q3 25 | $6.7B | $4.2B | ||
| Q2 25 | $6.8B | $4.1B | ||
| Q1 25 | $6.4B | $3.9B | ||
| Q4 24 | $6.1B | $3.9B | ||
| Q3 24 | $6.5B | $3.9B | ||
| Q2 24 | $5.9B | $3.9B | ||
| Q1 24 | $6.1B | $3.8B |
| Q4 25 | $13.4B | $7.4B | ||
| Q3 25 | $13.6B | $7.2B | ||
| Q2 25 | $13.7B | $7.1B | ||
| Q1 25 | $12.9B | $7.4B | ||
| Q4 24 | $12.6B | $7.3B | ||
| Q3 24 | $13.3B | $7.2B | ||
| Q2 24 | $13.8B | $7.3B | ||
| Q1 24 | $14.0B | $7.4B |
| Q4 25 | 0.60× | 0.28× | ||
| Q3 25 | 0.59× | 0.29× | ||
| Q2 25 | 0.61× | 0.29× | ||
| Q1 25 | 0.69× | 0.43× | ||
| Q4 24 | 0.70× | 0.43× | ||
| Q3 24 | 0.67× | 0.44× | ||
| Q2 24 | 0.96× | 0.44× | ||
| Q1 24 | 0.95× | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $257.5M |
| Free Cash FlowOCF − Capex | $46.0M | — |
| FCF MarginFCF / Revenue | 4.0% | — |
| Capex IntensityCapex / Revenue | 5.4% | — |
| Cash ConversionOCF / Net Profit | — | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $257.5M | ||
| Q3 25 | $219.0M | $247.5M | ||
| Q2 25 | $237.0M | $336.2M | ||
| Q1 25 | $-4.0M | $330.1M | ||
| Q4 24 | $177.0M | $217.9M | ||
| Q3 24 | $162.0M | $245.9M | ||
| Q2 24 | $200.0M | $148.8M | ||
| Q1 24 | $2.0M | $331.9M |
| Q4 25 | $46.0M | — | ||
| Q3 25 | $127.0M | — | ||
| Q2 25 | $180.0M | — | ||
| Q1 25 | $-69.0M | — | ||
| Q4 24 | $130.0M | — | ||
| Q3 24 | $120.0M | — | ||
| Q2 24 | $166.0M | — | ||
| Q1 24 | $-22.0M | — |
| Q4 25 | 4.0% | — | ||
| Q3 25 | 11.2% | — | ||
| Q2 25 | 14.5% | — | ||
| Q1 25 | -5.8% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | -1.8% | — |
| Q4 25 | 5.4% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 4.6% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 4.6% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | 21.55× | 1.42× | ||
| Q1 25 | -0.06× | 3.40× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | 0.45× | 4.85× | ||
| Q2 24 | — | 5.18× | ||
| Q1 24 | 0.06× | 3.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
